OPCH
Option Care Health, Inc.
OPCH has lower modeled downside risk, despite its lower overall score.
OSCR
Oscar Health, Inc.
OSCR has the edge over OPCH overall, supported by stronger fundamentals and stronger modeled upside.
OPCH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Healthy | |
| Stable |
OPCH's profitability and cash flow are currently healthy, and its revenue and balance sheet are stable.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
OPCH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 16x | $31.68 | — |
| Cheap | 20x | $27.79 | -12% |
| Current | 23x | $31.68 | — |
| Fair | 26x | $36.15 | +14% |
| Expensive | 38x | $52.50 | +66% |
Historical ranges are pointers, not guarantees.
OPCH's PE is in its cheap range at 23x. If earnings grow as analysts expect, today's price would be 16x next year's earnings.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over OPCH in the historical PE scenario, which offers more potential upside but is not a forecast.
OPCH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Growth | |
| Stable | |
| Limited | |
| High |
Analysts expect earnings and revenue growth for OPCH, with profitability holding steady.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
OSCR has the edge over OPCH on the outlook, with more favorable profitability expectations.
OPCH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.02 | +47% |
| Q3 2026 | $1.38 | +8.7% |
| Q2 2026 | $1.32 | +4.8% |
| Q1 2026 | $1.28 | +2.4% |
| Q4 2025 | $1.27 | +3.3% |
| Q3 2025 | $1.27 | +5.8% |
| Q2 2025 | $1.26 | +5% |
| Q1 2025 | $1.25 | -18% |
| Q4 2024 | $1.23 | -17% |
OPCH has the edge over OSCR on earnings, with more consistent year-over-year improvement.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
OPCH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.5B | +4.1% |
| Q2 2026 | $1.4B | +1.9% |
| Q1 2026 | $1.4B | +1.3% |
| Q4 2025 | $1.5B | +16% |
| Q3 2025 | $1.4B | +12% |
| Q2 2025 | $1.4B | +15% |
| Q1 2025 | $1.3B | +16% |
| Q4 2024 | $1.3B | +12% |
OPCH's revenue has grown year over year every quarter since late 2020: $1.5B last quarter, up 4.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 6% | +0.1 points |
| Q2 2026 | 5.9% | +0.1 points |
| Q1 2026 | 5.4% | -0.6 points |
| Q4 2025 | 6.2% | -0.7 points |
| Q3 2025 | 5.9% | -0.8 points |
| Q2 2025 | 5.8% | -0.7 points |
| Q1 2025 | 5.9% | -0.1 points |
| Q4 2024 | 6.9% | -0.6 points |
OPCH has the edge over OSCR on profitability, with a higher operating margin.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over OPCH on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
OPCH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $108M | -17% |
| Q2 2026 | $172.5M | +112% |
| Q1 2026 | -$21.2M | -$4.6M |
| Q4 2025 | $22.2M | -14% |
| Q3 2025 | $130.2M | -14% |
| Q2 2025 | $81.2M | -56% |
| Q1 2025 | -$16.6M | +$58M |
| Q4 2024 | $25.8M | -17% |
OPCH generated $282M in free cash flow over the past year, up 28% from the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over OPCH on cash flow, with more consistent year-over-year improvement.
OPCH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -2% | -3M shares |
| 1 year | -7.7% | -12.6M shares |
| 3 years | -17% | -30M shares |
| 5 years | -17% | -30.9M shares |
| Available history | -3.7% | -5.8M shares |
OPCH has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q4 2025 | $95.1M |
| Q3 2025 | $62.5M |
| Q4 2024 | $92.6M |
| Q3 2024 | $42M |
| Q2 2024 | $78.1M |
| Q1 2024 | $40.1M |
| Q4 2023 | $75.2M |
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
OPCH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 2.1x | Moderate |
| Q2 2026 | 2.4x | Moderate |
| Q1 2026 | 2.5x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 2.1x | Moderate |
| Q2 2025 | 2.3x | Moderate |
| Q1 2025 | 2.4x | Moderate |
| Q4 2024 | 1.8x | Healthy |
OPCH's net debt is about 2.1 years of its operating earnings (EBITDA), about the same as a year ago.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over OPCH on leverage, with a lower net debt burden relative to earnings.
OPCH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 69.8 | Neutral |
| Stochastic | 98.1 | Overbought |
OPCH's weekly RSI is 70 (neutral) and its Stochastic is 98 (overbought).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
OPCH PE vs Healthcare Sector
| Metric | OPCH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 32 | 29 | 3 pts above |
OPCH is trading at 23x earnings, a 11% discount to the Healthcare sector's median of 26x.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR has the edge over OPCH on valuation relative to its sector.
OPCH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $29.3 | 8.2% above |
| 20 week MA | $25.6 | 24% above |
| 50 week MA | $27.3 | 16% above |
| 100 week MA | $28.6 | 11% above |
| 200 week MA | $29.5 | 7.2% above |
OPCH has climbed back above all five of its weekly moving averages, and it's now 7.2% above its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR is in an uptrend: it's above all five of its weekly moving averages, and 106% above its 200-week average.
OPCH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $14.8 | $15.6 | +5.1% |
| 2021 | $15.6 | $28.0 | +80% |
| 2022 | $28.0 | $30.2 | +8.1% |
| 2023 | $30.2 | $33.7 | +11% |
| 2024 | $33.7 | $22.9 | -32% |
| 2025 | $22.9 | $32.6 | +43% |
| 2026 YTD | $32.6 | $31.7 | -2.8% |
OPCH has finished higher in five of the last six years. It's down 2.8% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over OPCH on returns for 2026, with the stronger performance.